Hemorrhagic Stroke
Clinical Trials Friday, June 7th, 2013Stroke: June 1, 2013
Intracerebral hemorrhage (ICH) accounts for 10% to 15% of all strokes. ICH continues to impart a considerable degree of morbidity and mortality, with 30-day mortality ranging from 44% to 50%.1–3 ICH remains a devastating disease, and current treatment options lag far behind those for ischemic stroke.
There are no approved therapies, which improve outcome, and treatment remains mainly supportive. Despite the lack of available acute treatment options for ICH, the past decade of clinical and preclinical research has identified important concepts in its pathophysiology and how this information might be used in developing treatment. Read more